Drugs.com Clinical Trial ResultsOriginal article
Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-Specific Agonist of the Wingless-Related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema
Phase 2remigromigNeutral
AI Analysis
Summary
Merck announced the first one-year results presentation from the pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig, a tri-specific agonist of the Wnt pathway, in adults with diabetic macular edema.
Clinical Trial Data
Phase
2b/3
Outcome Details
One-year results from pivotal Phase 2b/3 BRUNELLO trial presented
Importance:6/10
Sentiment:
0.00
Phase 2b/3Data ReadoutDiabetic Macular EdemaWnt PathwayTri-Specific Agonist
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on October 10, 2026 11:10 PM